Shinobi Therapeutics

Recent Finacing

Grant ext

Recent Raise

$59M

Shinobi Therapeutics develops off-the-shelf, immune-evasive allogeneic CD8αβ iPSC-derived T cell therapies (Katana platform) targeting GPC3+ solid tumors, with partnerships for TCR discovery and scaled manufacturing.

Founded 2023

California, United States

11-50

Private

shinobitx.com

Highlights

Focus Areas

Biotechnology

Health Care

Therapeutics

Recent Investors

Financials

$110M

Total Raised

2

Funding rounds

8

Investors

Team

Upgrade to view the team

See the team members at Shinobi Therapeutics.